Key result
Gene therapy targeting inflammation suppresses atherogenesis in animal models, but clinical application is challenged by vector-related immune responses and insufficient local expression.
Why the study?
Does gene therapy targeting inflammation and oxidative stress suppress atherogenesis in animal models?
Population
Animal models of atherosclerosis
Design
Review
Authors
Loading...
Should not change clinical practice for atherosclerosis; leaves open whether refined vectors can overcome immune and expression barriers in trials.
Does gene therapy targeting inflammation and oxidative stress suppress atherogenesis in animal models?
While gene therapy targeting inflammation and oxidative stress suppresses atherogenesis in animal models, significant translational barriers prevent its current clinical application.
Van-Assche et al. (2011) conducted a review in Atherosclerosis. Gene therapy targeting inflammation was evaluated. Gene therapy targeting inflammation suppresses atherogenesis in animal models, but clinical application is challenged by vector-related immune responses and insufficient local expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: